Biotechnology
Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs
TOKYO, Aug. 28, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hema...
2025-08-28 22:00
1244
D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers
* Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment with platinum-based chemotherapy and anti-PD-(L)1 antibody but have not been previously treate...
2025-08-28 21:00
3441
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
2025-08-28 20:00
2696
WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi
* Committed to net-zero across the value chain by 2050 * Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation * Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, Aug. 28, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract ...
2025-08-28 17:00
2741
Exyte and JGC Launch "Nixyte" - New EPC Brand for High-Tech Industries in Southeast Asia
* Exyte and JGC introduce new EPC brand "Nixyte"; specializing in semiconductors, biopharma, data centers, and battery facilities * Focus on high-tech industries in Southeast Asia; Serving Indonesia, Philippines, Vietnam, and Thailand * Exyte CEO Dr. Wolfgang Büchele: "Nixyte unites Exyte'...
2025-08-28 10:00
1635
ACROBiosystems and DAAN Biotherapeutics Sign Strategic MOU for the Development of Precision Immuno-Oncology Therapeutics
SEOUL, South Korea, Aug. 28, 2025 /PRNewswire/ -- ACROBiosystems, a global biotechnology company dedicated to accelerating the drug development process through innovative tools and solutions, announced that it has entered into a strategic Memorandum of Understanding (MOU) with DAAN Biotherapeutic...
2025-08-28 09:54
1901
Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study
- ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison. - Higher drug exposure and favorable tolerability profile positions ASC30 oral once-daily tablet favorably compared to orforglipron...
2025-08-28 07:45
1310
Harbour BioMed Reports 2025 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its i...
2025-08-27 22:40
2201
Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0
Start Your Journey to Access Vast Chemical Space CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Developing new medicines demands smart technology and powerful tools. DNA-encoded library (DEL) technology, with its unique ability to rapidly screen billions of compounds to identify small molecule hi...
2025-08-27 21:30
1600
Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states
Phase 2b/3 Alzheimer's trial enrolment passes 50% - twenty US trial sites continuing to recruit participants SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet for...
2025-08-27 20:00
1437
Innovent Announces 2025 Interim Results and Business Updates
* Robust revenue growth and substantial profit improvement * Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China, Aug. 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class bioph...
2025-08-27 18:08
3082
Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress. Financially, the company achieved record revenue, driven by the strong performance of its core produ...
2025-08-27 14:02
1109
Crescom to Showcase Musculoskeletal AI Innovations at 26th Asian Musculoskeletal Society Annual Meeting
Company to present MediAI solution suite and strengthen partnerships for expansion across Southeast andEast Asia SEOUL, South Korea, Aug. 27, 2025 /PRNewswire/ -- Crescom, a leader in AI-powered musculoskeletal (MSK) image analysis software, announced its participation in the 26th Asian Musculos...
2025-08-27 09:00
1498
Cerecin Joins NIHR HealthTech Research Centre in Brain Health as an Industry Partner
DENVER, Aug. 27, 2025 /PRNewswire/ -- Cerecin, a global biotech company focused on neurometabolism, is proud to announce its partnership with the NIHR HealthTech Research Centre (HRC) in Brain Health, joining a distinguished group of industry leaders including GE Healthcare, Novo Nordisk, Roche D...
2025-08-27 00:04
1474
iNtRON Bio, files Two Patent Applications for IMPA™ Platform-Based Gene Editing Technology
* Development of gene-editing technology for Pasteurella bacteriophages using the IMPA™ platform * Establishment of an advanced platform technology based on CRISPR-Cas9 and recombination forPasteurella * Patent applications filed for core proprietary technology enabling the incorporation of...
2025-08-26 21:00
1164
Fosun Pharma Announces 2025 Interim Results
Enhancing Innovation Efficiency and Steadily Expanding Globally SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced ...
2025-08-26 20:42
2306
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
* Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for millions of Thais * This approval builds on Abbott's biosimilar portfolio in Asia Pacific, following recent launches inMalaysia and Indi...
2025-08-26 14:29
1844
Neopharma Technologies and Orient Gene Partner to Digitize Healgen® Drug Test Portfolio Globally with NEOVAULT®
Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities WASHINGTON, Aug. 26, 2025 /PRNewswire/ -- Neopharma Technologies Limited ("Neopharma") today announced it hasentered into a global software licensing and collaboration agreement with Zhejian...
2025-08-26 02:10
1576
Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius' revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390....
2025-08-25 21:18
3065
Everest Medicines Announces Participation in September Investor Conferences
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fin...
2025-08-25 20:57
1740
Week's Top Stories
Most Reposted
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 323 media titles]
2026-02-02 10:00
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 315 media titles]
2026-02-03 11:00
Mastercard Launches Portfolio of Fleet Solutions in Asia Pacific
[Picked up by 311 media titles]
2026-02-04 09:00Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 305 media titles]
2026-02-03 12:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 288 media titles]
2026-02-01 19:35Most Read
Origin Agritech Announces Fiscal Year 2025 Results
2026-01-31 06:00
8814
Photo Dance: Making AI Dance Trends Accessible to Everyone - How This App Lets Ordinary Users Join the Dance Wave Without Appearing On Camera
2026-01-31 00:00
7058
Planet Green Holdings Corp. Provides Response to Unusual Market Action
2026-01-31 05:05
6842
